ReviewHuman genomics2025
Increasing pathogenic germline variant diagnosis rates in precision medicine: current best practices and future opportunities.
Review in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning for extracellular vesicles enables diagnostic and therapeutic nanobiotechnology.Journal of nanobiotechnology · 2026Review
- Beyond the Exome: The Role of Noncoding and Regulatory Variants in Monogenic Diseases.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The accurate diagnosis of pathogenic variants is essential for effective clinical decision making within precision medicine programs. Despite significant advances in both the quality and quantity of molecular patient data, diagnostic rates remain suboptimal for many inherited diseases. As such, prioritisation and identification of pathogenic disease-causing variants remains a complex and rapidly evolving field. This review explores the latest technological and computational options being used to increase genetic diagnosis rates in precision medicine programs.While interpreting genetic variation via standards such as ACMG guidelines is increasingly being recognized as a gold standard approach, the underlying datasets and algorithms recommended are often slow to incorporate additional data types and methodologies. For example, new technological developments, particularly in single-cell and long-read sequencing, offer great opportunity to improve genetic diagnosis rates, however, how to best interpret and integrate increasingly complex multi-omics patient data remains unclear. Further, advances in artificial intelligence and machine learning applications in biomedical research offer enormous potential, however they require careful consideration and benchmarking given the clinical nature of the data. This review covers the current state of the art in available sequencing technologies, software methodologies for variant annotation/prioritisation, pedigree-based strategies and the potential role of machine learning applications. We describe a key set of design principles required for a modern multi-omic precision medicine framework that is robust, modular, secure, flexible, and scalable. Creating a next generation framework will ensure we realise the full potential of precision medicine into the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.